BioCentury | Apr 2, 2012
Clinical News
Spartan RX CYP2C19: Phase II/III data
...The open-label, Canadian Phase II/III RAPID GENE trial in 187 patients showed that Spartan's Spartan RX CYP2C19 test...
...stable angina to be randomly assigned to rapid point-of-care genotyping for CYP2C19 mutations with the Spartan RX CYP2C19...
...Data were published in The Lancet. In 2010, Spartan received CE Mark approval for its Spartan RX CYP2C19...
...stable angina to be randomly assigned to rapid point-of-care genotyping for CYP2C19 mutations with the Spartan RX CYP2C19...
...Data were published in The Lancet. In 2010, Spartan received CE Mark approval for its Spartan RX CYP2C19...
